Takehiro Tozuka, Rintaro Noro, Keisuke Yoshida, Satoshi Takahashi, Mariko Hirao, Kuniko Matsuda, Yasuhiro Kato, Shinji Nakamichi, Susumu Takeuchi, Masaru Matsumoto, et al. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer. JTO clinical and research reports. 2024. 5. 4. 100668-100668
Satoshi Watanabe, Naoki Furuya, Atsushi Nakamura, Jun Shiihara, Ichiro Nakachi, Hisashi Tanaka, Mika Nakao, Koichi Minato, Masahiro Seike, Shinichi Sasaki, et al. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). European journal of cancer (Oxford, England : 1990). 2024. 197. 113469-113469
Satoshi Watanabe, Naoki Furuya, Atsushi Nakamura, Jun Shiihara, Ichiro Nakachi, Hisashi Tanaka, Mika Nakao, Koichi Minato, Masahiro Seike, Shinichi Sasaki, et al. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). European journal of cancer (Oxford, England : 1990). 2023. 197. 113469-113469
Yuto Terashima, Masaru Matsumoto, Hiroki Iida, Sae Takashima, Aya Fukuizumi, Susumu Takeuchi, Akihiko Miyanaga, Yasuhiro Terasaki, Kazuo Kasahara, Masahiro Seike. Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC. JTO clinical and research reports. 2023. 4. 11. 100578-100578
Takehiro Tozuka, Rintaro Noro, Keisuke Yoshida, Satoshi Takahashi, Mariko Hirao, Kuniko Matsuda, Yasuhiro Kato, Shinji Nakamichi, Susumu Takeuchi, Masaru Matsumoto, et al. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer. JTO clinical and research reports. 2024. 5. 4. 100668-100668
Satoshi Watanabe, Naoki Furuya, Atsushi Nakamura, Jun Shiihara, Ichiro Nakachi, Hisashi Tanaka, Mika Nakao, Koichi Minato, Masahiro Seike, Shinichi Sasaki, et al. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). European journal of cancer (Oxford, England : 1990). 2024. 197. 113469-113469